HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NuGene Growing Its Stem-Cell Cosmeceuticals Biz; Regulatory Risks Noted

This article was originally published in The Rose Sheet

Executive Summary

NuGene's sales have soared with expanded distribution, but increased regulation continues to be a risk to its human stem-cell-based cosmeceuticals business, the firm notes. Skin and hair-care line extensions will launch later this year, and the company is considering developing an in-house sales force.

You may also be interested in...



AIVITA Stem Cell Skin Care; Scent Republik Fragrance Stiks For Tweens; More Cosmetics Product News

AIVITA Biomedical plans to support its clinical cancer development programs with revenue from a skin-care line featuring its proprietary stem cell technology; Scent Republik, founded by two dads as a fresh take on kid's cosmetics, launches fragrance "stiks." More news in brief.

FDA Shows Skin Authority Who’s Boss With Warning For Drug Claims

Yet another skin-care marketer, Skin Authority, has been served with an FDA warning letter for excessive product claims that identify its offerings as drugs. The agency cites statements touting the firm’s ingredient benefits, including collagen production, improved circulation, inflammation relief and hyperpigmentation treatment, consistent with other warnings issued to cosmetics firms in recent months.

Stem-Cell Cosmeceutical Firm NuGene Eyes Skin-Care Drug Approvals

Acne treatments and burn-relief products based on human stem-cell media may be forthcoming from NuGene International, as newly created subsidiary NuGene BioPharma looks to parlay the firm’s existing technology into skin-care pharmaceuticals subject to FDA approval.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel